PMID- 36638601 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20230227 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 63 DP - 2023 Apr TI - Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study. PG - 152108 LID - S1092-9134(23)00005-9 [pii] LID - 10.1016/j.anndiagpath.2023.152108 [doi] AB - OBJECTIVES: The purpose of this study was to investigate the clinicopathological characteristics of primary central nervous system lymphoma (PCNSL). METHODS: We collected 41 PCNSL formalin-fixed, paraffin-embedded (FFPE) samples from human immunodeficiency virus (HIV)-positive patients and performed HE (haematoxylin-eosin) staining, immunohistochemistry (IHC) staining, in situ hybridization, fluorescence in situ hybridization (FISH). Real-time quantitative polymerase chain reaction (RT-qPCR) was performed in 9 cases of FFPE samples. Meanwhile, we analysed the clinical pathological significance of the results. RESULTS: Seven patients had diffuse large B-cell lymphoma (DLBCL) with germinal centre B-cell (GCB)-like DLBCL, 32 had activated B-cell (ABC)-like DLBCL, and 2 had Burkitt lymphoma (BL). GCB-like DLBCL patients were older at onset (P = 0.040).A lower CD4(+) T-cell count and a decrease in cerebrospinal fluid (CSF) glucose content were more frequent in ABC-like DLBCL (P = 0.012, P = 0.006). Overexpression of P53 was more in ABC-like DLBCL (P = 0.041). 73.2 % cases were Epstein-Barr encoding region (EBER) positive, which was more likely in ABC-like DLBCL patients (P = 0.037). EBV DNA were detected in 5/7 EBER-negative DLBCL cases and none (0/2) of the BL cases. All the cases were negative for HHV8 staining. None of the 7 Double expressor lymphoma (DEL) cases had BCL2, BCL6, or c-MYC genetic rearrangements. CONCLUSIONS: HIV-related PCNSL showed unique clinical pathological significance. None of EBV detected in HIV-related BL and without HHV8 infectious are new sights in our single-center study of Chinese HIV-related PCNSL patients. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Chen, Jiamin AU - Chen J AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Sun, Lei AU - Sun L AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Dai, Yuyang AU - Dai Y AD - National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. FAU - Zhang, Liang AU - Zhang L AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Yang, Kun AU - Yang K AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Han, Xiaoyi AU - Han X AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Ding, Xinghuan AU - Ding X AD - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Gao, Haili AU - Gao H AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Zhou, Xingang AU - Zhou X AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. FAU - Wang, Peng AU - Wang P AD - Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. Electronic address: chinaroc001@126.com. LA - eng PT - Journal Article DEP - 20230107 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 SB - IM MH - Humans MH - Central Nervous System/pathology MH - East Asian People MH - *HIV Infections/complications MH - In Situ Hybridization, Fluorescence MH - *Lymphoma, Large B-Cell, Diffuse/pathology MH - Retrospective Studies OTO - NOTNLM OT - Clinical pathology OT - HIV OT - Primary central nervous system lymphoma (PCNSL) COIS- Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/14 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/01/13 18:07 PHST- 2022/09/01 00:00 [received] PHST- 2022/12/13 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/14 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/13 18:07 [entrez] AID - S1092-9134(23)00005-9 [pii] AID - 10.1016/j.anndiagpath.2023.152108 [doi] PST - ppublish SO - Ann Diagn Pathol. 2023 Apr;63:152108. doi: 10.1016/j.anndiagpath.2023.152108. Epub 2023 Jan 7.